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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYFamilial transthyretin amyloidosis (ATTR) is an autosomal-dominant protein-folding disorder caused by over 100 distinct mutations in
the transthyretin (TTR) gene. In ATTR, protein secreted from the liver aggregates and forms fibrils in target organs, chiefly the heart and
peripheral nervous system, highlighting the need for amodel capable of recapitulating themultisystem complexity of this clinically var-
iable disease. Here, we describe the directed differentiation of ATTR patient-specific iPSCs into hepatocytes that producemutant TTR, and
the cardiomyocytes and neurons normally targeted in the disease. We demonstrate that iPSC-derived neuronal and cardiac cells display
oxidative stress and an increased level of cell death when exposed to mutant TTR produced by the patient-matched iPSC-derived hepa-
tocytes, recapitulating essential aspects of the disease in vitro. Furthermore, small molecule stabilizers of TTR show efficacy in thismodel,
validating this iPSC-based, patient-specific in vitro system as a platform for testing therapeutic strategies.INTRODUCTION
Amyloidosis refers to a group of diseases caused by the
extracellular deposition of misfolded fibrillar proteins,
leading to multiorgan failure and death (Falk et al., 1997).
Familial amyloidosis (AF) occurs when inherited point
mutations in the genes coding for abundant serum pro-
teins such as transthyretin (TTR), fibrinogen, lysozyme,
or apolipoproteins lead to clinical disease. The most com-
mon form of AF arises from aggregation of mutated TTR,
a 55 kDa transport protein predominantly synthesized by
the liver (Connors et al., 2003; Falk et al., 1997; Plante´-
Bordeneuve and Said, 2011). Familial transthyretin
amyloidosis (ATTR) is a lethal, autosomal-dominant dis-
ease caused by single amino acid substitutions arising
from 1 of more than 100 described mutations in the TTR
gene (Connors et al., 2003; online amyloidosis mutation
database in Rowczenio and Wechalekar [2010]). These sin-
gle amino acid substitutions destabilize the native homote-
trameric structure of circulating TTR, promoting release of
amyloidogenic TTRmonomers, fibril formation, and depo-
sition as amyloid in target end organs (Ando et al., 2005;
Falk et al., 1997). Most amyloidogenic TTR variants target
the nervous system and heart, inducing neuropathy and
cardiomyopathy (Jacobson et al., 1992, 1997; Plante´-
Bordeneuve and Said, 2011). The organ distribution and
age of onset can vary across families and endemic areas,Stem Cell Reven with identical TTR mutations. Although transgenic
mouse models and immortalized human cell lines have
provided some insights into disease pathogenesis (Araki
et al., 1994; Kohno et al., 1997; Reixach et al., 2004; Sousa
et al., 2002; Tagoe et al., 2007), these systems are indepen-
dent of the genetic context of the patient.
ATTR represents an important unmet medical need with
significant morbidity and early mortality in affected fam-
ilies. Survival after ATTR disease onset is usually only
5–15 years (Benson et al., 2011; Plante´-Bordeneuve and
Said, 2011). Orthotopic liver transplantation is currently
the only US-approved treatment for ATTR. However, only
about one-third of patients are candidates for surgery
(Monteiro et al., 2004), and cardiomyopathy and neu-
ropathy may continue to worsen after transplantation.
Recently, small molecule stabilizers of variant TTR (Tafami-
dis and diflunisal) shown to inhibit amyloid fibril forma-
tion in vitro are being studied in clinical trials (Berk et al.,
2012; Coelho et al., 2012). Patient-specific, cell-based
models are needed to facilitate the study of the genetic
and epigenetic factors in this disease, permitting pharma-
cogenomic assessments of novel therapeutics.
The generation of induced pluripotent stem cells (iPSCs)
through the reprogramming of somatic cells from patients
with inherited diseases provides an unprecedented oppor-
tunity to study the effects of genetic abnormalities and dis-
ease progression. The derivation of unlimited quantities ofeports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The Authors 451
Figure 1. Schematic Summary of the
In Vitro iPSC Approach to Study ATTR
The cytokines that were used in each dif-
ferentiation protocol are indicated. FAP,
familial amyloid polyneuropathy; FAC,
familial amyloid cardiomyopathy.
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iPSC-Based Modeling of Familial TTR Amyloidosisthe relevant cell types targeted and affected in patients
with hereditary disease allows for the investigation of the
cellular, molecular, and epigenetic events involved in a
multisystem, genetic disease such as ATTR. Although
most cases of ATTR are due to a single base pair mutation
predominantly expressed in the liver, end organ damage
occurs outside the liver, highlighting the need for a model
capable of recapitulating the multisystem complexity of
the disease.
Here, we describe the generation of ATTR patient-specific
iPSCs and the directed differentiation of these cells into
hepatic, neuronal, and cardiac lineages thereby modeling
the three major tissue types involved in this disease (Fig-
ure 1). Our data are consistent with the clinical trial find-
ings that known small molecule TTR stabilizers can inhibit
TTR fibril formation in vivo, validating patient-specific
iPSCs as a platform for testing therapeutics.RESULTS
Generation of ATTR Disease-Specific Human iPSCs
Using our highly efficient and reproducible STEMCAA re-
programming system (Somers et al., 2010; Sommer et al.,
2009, 2010), we generated iPSC lines from tissue samples
of a patient heterozygous for the leucine-55-proline
(L55P) TTR mutation (see Figure S1A available online).
This mutation, one of the most clinically aggressive vari-
ants of ATTR disease (Jacobson et al., 1992), produces a
highly unstable and amyloidogenic TTR, clinically target-452 Stem Cell Reports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 Theing the heart and the peripheral nervous system (Lashuel
et al., 1999). The sequenced TTR transcript from the reprog-
rammed ATTR-iPSC derivatives was compared to that from
control iPSCs to confirm that the ATTR iPSCs carried the
L55P mutation (Figure S1B). Characterization of each
iPSC clone demonstrated normal 46 XX karyotype, expres-
sion of stem cell marker genes, and pluripotency in tera-
toma assays (Figures S1C–S1F). Characterized clones were
then differentiated into both the effector cells (hepato-
cytes) that produce mutant TTR and peripheral target cells
(neurons and cardiomyocytes) that are damaged by expo-
sure to aberrant protein in order to create an iPSC-based,
in vitro model of ATTR (Figure 1).
ATTRL55P Disease-Specific Human iPSCs Can Be
Directed into Hepatic-Lineage Cells that Secrete TTR
In ATTR, the deleterious effects of liver-produced TTR vari-
ants are seen in other organs, with the liver remaining
phenotypically normal. The majority of patients with
ATTR are heterozygous for one autosomal-dominant muta-
tion in the TTR gene, although compound heterozygotes
have been documented (Connors et al., 2003, 2009; Ham-
marstro¨m et al., 2001). Therefore, in most patients, TTR
tetramers synthesized by the liver are comprised of a mix
of normal and variant TTR monomers that assemble
into stochastically formed homo- and heterotetramers
(Schneider et al., 2001). To derive the full complement of
TTR tetramer variants, containing posttranslational modi-
fications that are normally present in patient serum TTR,
we differentiated ATTRL55P iPSCs into hepatic-lineage cellsAuthors
Stem Cell Reports
iPSC-Based Modeling of Familial TTR Amyloidosiswith the aim of producing variant TTR protein from
patient-derived cells.
In our system, the derivation of hepatic-lineage cells
from iPSCs was achieved through a sequential, growth fac-
tor-driven differentiation process (Hay et al., 2008; Sullivan
et al., 2010) (Figure 2A). Mimicking signaling events that
occur during embryonic patterning, high levels of activin
A and Wnt3a were used to drive iPSCs toward a definitive
endoderm progenitor state. At this stage, the majority
of the cells stained positively for CXCR4 and/or cKit
(Figure 2B), cell surface markers for definitive endoderm
(Yasunaga et al., 2005). Further maturation of the hepat-
ic-lineage cells was achieved through culturing in matura-
tion media containing hepatocyte growth factor (HGF)
and oncostatin M (OncM). As determined by quantitative
PCR, the resultant hepatic-lineage cells express robust
levels of hepatic markers apolipotein A1 (APOA1), albumin
(ALB), alpha-fetoprotein (AFP), and, also importantly, TTR
(Figure 2C).
Similarly, efficient derivation of hepatic-lineage cells and
their precursor cell types was achieved from both ATTRL55P
iPSCs and a control iPSC line as judged by comparable
CXCR4 and cKit stainings at day 5 of differentiation (Fig-
ures 2B and S2A), TTR gene expression (Figure S2B), and
functionally, the iPSC-derived, hepatic-lineage cells were
capable of glycogen storage as determined by periodic
acid Schiff (PAS) staining (Figures 2D and S2C). For the
purposes of our in vitro disease model, we investigated
whether the ATTRL55P iPSC-derived hepatic cells were
capable of synthesizing and secreting TTR protein.Western
blot analysis of serum-free conditioned media (hepatic
supernatant [hs]) produced from ATTRL55P hepatic-lineage
cells revealed the presence of TTR protein, indicating that
iPSC-derived hepatic-lineage cells were indeed capable of
TTR protein production and secretion, with the concentra-
tion of TTR in hs estimated to be in the range of 25–50 nM
(Figure 2E). Moreover, mass spectrometric analysis was uti-
lized to precisely characterize mutant and wild-type (WT)
forms of TTR in hs, revealing the presence of the TTRL55P
species only in supernatant derived from ATTRL55P
hepatic-lineage cells (Figure 2F). As expected, the presence
of TTRWTwas detected in both control and ATTRL55P super-
natants (Figure 2F). The ratio of ATTRL55P-to-TTRWT mono-
mers in ATTR hs was calculated to be 1:2 rather than 1:1 as
expected, suggesting that a proportion of the TTRL55P pro-
duced in hepatic-lineage cells is not secreted into the
media, for reasons that are unknown.
Although it is the site of aberrant protein production in
ATTR, the livers of patients with ATTR are thought to be
relatively normal, escaping the cellular damage seen in
other target tissues. However, there is some evidence to
suggest that there could be physiological andmolecular dif-
ferences in ATTR livers. Examination of the liver in a trans-Stem Cell Rgenic murine model for a different form of amyloidosis,
SSA (which involves the deposition of WT TTR), revealed
a link between the levels of protein folding/chaperoning
genes in the liver, and the degree of observable TTR deposi-
tion in the ‘‘target’’ cardiac tissue in aged transgenic mice.
The livers of the young transgenic mice also exhibited
increased expression of genes linked to protein trafficking
and inflammation/immunity (Buxbaum et al., 2012).
Although control and ATTRL55P iPSC-derived hepatic
cells express similar levels of hepatic markers, we were
interested in the possible existence of gene expression
signature differences between the two cell populations.
To examine if this was the case, we performed microarray
analysis to compare the transcriptomes of hepatic-stage
cells derived from normal versus ATTRL55P iPSCs (three in-
dependent replicates per sample type). Hierarchical clus-
tering analysis indicated segregation of the ATTRL55P
iPSC-derived biological triplicates from the control samples
(Figure S3A). KEGG and Biocarta analysis of the data set re-
vealed that extracellular matrix and connective tissue
genes including collagen, laminin, and integrin transcripts
were overrepresented in control hepatic cells (Figures S3B
and S3C). Interestingly, genes relating to protein folding
and stress response, especially the heat shock protein 70
(hsp70) family genes, were among the main genes upregu-
lated in ATTRL55P hepatic cells (Figures S3B–S3D), suggest-
ing that the in-vitro-derived, disease-specific hepatic cells
upregulate these genes in response to the aberrant TTR
protein.
ATTRL55P iPSCsCanBeDirected into Target Cells of the
Disease: Cardiomyocytes and Neurons
The liver is not a clinically important site of amyloid depo-
sition in vivo. Recapitulation of the ATTR disease pheno-
type requires a multilineage system to model complex
interactions between the liver and target organ systems,
including epigenetic events required for the full clinical
phenotype to develop. The flexibility of the iPSC-based sys-
tem allows for the directed differentiation of other tissue
types, such as cardiomyocytes and neurons, that are
affected by the variant protein produced by the liver. In
initial studies, ATTRL55P iPSC-derived cardiac and neuronal
cells were characterized with regards to gene expression
profiling and functional assays.
The derivation of cardiomyocytes from ATTRL55P iPSCs
was achieved using two methods. First, a modified
growth factor-driven approach (Kattman et al., 2011;
Yang et al., 2008) was used to efficiently obtain beating
cardiomyocytes after 21 days of differentiation. A tradi-
tional embryoid body (EB) differentiation approach also
successfully yielded beating cardiomyocyte colonies after
only 10 days of differentiation (Figure 3A; Movie S1).
A side-by-side comparison of the two methods througheports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The Authors 453
Figure 2. Generation and Characterization of ATTRL55P iPSC-Hepatic Lineage Cells
(A) Schematic diagram details the stepwise differentiation protocol used to obtain hepatic-lineage cells from iPSCs.
(B) Cells at day 5 of differentiation express the definitive endoderm cell surface markers CXCR4 and cKit, as determined by FACS
analysis.
(legend continued on next page)
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Figure 3. Generation of Beating Cardio-
myocytes from ATTRL55P iPSCs
(A) Day 14 contracting EBs are presented.
(B) Quantitative PCR analysis of ATTRL55P
iPSC and ATTRL55P day 14 cEB cultures is
shown. The pluripotency marker Oct4
is downregulated, and cardiac markers
(Nkx2.5, Tbx5, Islet1, cardiac actin, and the
end-stage marker cardiac troponin) are
upregulated in the latter sample type. All
values are normalized to GAPDH. Indepen-
dent sample sizes are iPSC n = 2 and cEB
n = 3. Error bars, SD.
(C) Intracellular FACS was used to quanti-
tate the proportion of cells that express
the cardiac marker sarcomeric anti-actinin
(blue peak) in day 13 cEB cultures. The
isotype control peak is shown in red.
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was more efficient at yielding cardiomyocyte cells (as
judged by the end-stage cardiomyocyte marker cTNT) (Fig-
ure 3B; data not shown). In addition to this, a high propor-
tion of cells in cardiac EB (cEB) cultures express the cardiac
marker sarcomeric anti-actinin as determined by intracel-
lular FACS analysis (Figure 3C), and this method was there-
fore used to generate cardiomyocytes for subsequent
experiments.
For the derivation of neuronal-lineage cells, a modified
stepwise-directed differentiation approach was used to
obtain neuronal-lineage cells from iPSCs based on a previ-
ously described protocol by Chambers et al. (2009) and Hu
et al. (2009). Morphologically, the cells produced resemble
neuronal cells with long dendritic processes and axon-like
structures (Figure 4A). Immunofluorescence characteriza-
tion revealed that early-stage cells were positive for
neuronal class III b-tubulin (TUJ1) (Figure 4B), whereas
late-stage differentiation cells expressed microtubule-asso-
ciated protein 2 (MAP2) and choline acetyltransferase
(ChAT), proteins that localize to the cytoplasm of neuronal
cells and the latter an enzyme that is critical for the produc-(C) Hepatic markers AFP, ALB, APOA1, and TTR are upregulated in h
(precursor cell type) definitive endoderm cells. All values are normalize
biological samples).
(D) Hepatic-lineage cells derived from ATTRL55P iPSCs morphologica
demonstrated by PAS staining.
(E) ATTRL55P iPSC hepatic-lineage cells produce and secrete TTR protein
Recombinant human TTR (25 ng) and serum-free media alone serve as p
the ATTRL55P hs and media-only lanes, is a result of the nonspecifi
formulation.
(F) Mass spectrometry analysis of control and ATTRL55P hs for TTR s
contained both WT (13,759 kDa) and L55P (13,742 kDa) forms of TTR p
former was detectable in control samples.
Stem Cell Rtion of the neurotransmitter acetylcholine (Figure 4C).
Real-time PCR analysis demonstrated the expression of
transcripts for TUJ1 and homeobox protein 9 (HB9), a
motor neuron-specific marker (Figure 4D).
Studies have suggested that target cells affected by amy-
loidogenic TTR internalize and modify the variant protein
in a process that may contribute to fibrillogenesis (Fleming
et al., 2007, 2009). We examined whether ATTRL55P iPSC
neuronal-lineage cells were capable of taking up fluores-
cently labeled WT or L55P recombinant human TTR pro-
tein. As demonstrated in Figure 4E, cells incubated with
either labeled WT or L55P TTR contained foci of fluores-
cence in the cytoplasm, demonstrating that the cells were
indeed capable of TTR internalization, similar to their
in vivo counterparts. Interestingly, iPSC-derived cardiac
cells did not demonstrate this property (data not shown).
Patient-Specific Recapitulation of Target Tissue
Damage In Vitro
Having successfully derived the tissue types involved in
ATTRL55P from patient-specific iPSCs, we then assessed
the cellular and molecular effects of exposure to aberrantepatic-lineage cells. These markers are not expressed in iPSCs or
d to GAPDH. Error bars represent the SD (n = 3 up to six independent
lly resemble hepatocytes and are capable of glycogen storage as
as demonstrated by immunoblot analysis with media supernatants.
ositive and negative controls, respectively. The lower band, seen in
c cross-reactivity of the TTR antibody to a product in the media
pecies is shown. hs generated from ATTRL55P hepatic-lineage cells
rotein (labeled black and red arrows, respectively), whereas only the
eports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The Authors 455
Figure 4. Derivation of Neuronal-Lineage Cells from ATTRL55P
iPSCs that Are Capable of TTR Internalization
(A) Phase-contrast image shows neuronal cells derived from
ATTRL55P iPSCs.
(B) Immunofluorescence staining presents ATTRL55P iPSC-derived
neuronal cells for the neuronal marker TUJ1 (red). Nuclei were
stained with DAPI (blue).
(C) Immunofluorescence staining shows ATTRL55P iPSC-derived
neuronal cells for the MAP2 (red). Nuclei were stained with DAPI
(blue).
(D) Quantitative PCR analysis of derived neuronal-lineage cells
compared to undifferentiated iPSCs and human brain cDNA is
shown. Neuronal cells exhibit upregulated levels of TUJ1 and
motor neuron homeobox transcription factor HB9. All indepen-
dent biological samples (n = 3) were normalized to GAPDH. Error
bars, SD.
(E) ATTRL55P iPSC neuronal-lineage cells are capable of TTR (both
WT and L55P) internalization as demonstrated by exposure to
456 Stem Cell Reports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The
Stem Cell Reports
iPSC-Based Modeling of Familial TTR AmyloidosisTTR in the directly differentiated target cells. To do this,
serum-free conditioned media (hs) were harvested from
control and ATTRL55P iPSC-derived hepatic cells for use in
subsequent TTR exposure experiments in the neuronal-
and cardiac-lineage target cells.
ATTRL55P iPSC-derived neuronal and cardiac-lineage cells
were cultured with media containing either control or
ATTRL55P hs, which was added to normal culture media
in a 1:1 ratio. After an extended period of exposure
(R12 days), there was no noticeable difference in the
morphology of the neuronal cells, and no visible protofila-
ments or aggregateswere present in the cultures (Figure 5A).
Similar observations were made for the cardiac cells after
6–10 days of exposure (Figure 5B). These results were in
contrast to those seen when iPSC-derived neuronal cells
and a neuroblastoma cell line (SY5Y) were exposed to
human recombinant L55P TTR protein; clear aggregate for-
mation was noted in these cultures, but not in cultures
dosed with WT TTR protein (Figures S4A and S4B). The
L55P protein aggregates stained positively for the ATTR
amyloid binding chemical, thioflavin T (Figure S4C).
Although there was no observable difference in the
morphology of cells exposed to either control or ATTRL55P
hs, a number of genes previously reported to be associated
with ATTR disease progression were upregulated in both
iPSC-derived neuronal and cardiac cells exposed to
ATTRL55P hs. In particular, the stress-response markers,
macrophage colony stimulating factor (M-CSF) and heme
oxygenase 1 (HO1), were upregulated (Figures 5C and 5D;
asterisks denote statistically significant differences as
compared to control samples, as determined by Student’s
t test analysis). These genes were previously reported to
be associated with ATTR in murine model systems and in
neuronal biopsy samples of patients with ATTR (Sousa
et al., 2001a, 2001b, 2005). The expression of protein
folding genes was also examined in control and ATTRL55P
hs-exposed cells based on the observation that higher
levels of these genes were seen in ATTRL55P iPSC-derived
hepatic-lineage cells (compared to disease-free controls)
by microarray analysis (Figure S3). Of the interrogated
genes, the hsp70 gene, hspA1A, was upregulated in
neuronal-lineage cells exposed to ATTRL55P hs, but not to
a significant level (Figures 5C and 5D).
In addition to these marked gene expression changes,
Hoechst 33342 and propidium iodide (H-PI) staining re-
vealed that both neuronal and cardiac cells exposed to
ATTRL55P hs displayed statistically significant decreased
cell survival, although no overt morphological changes
were noted. Cell survival was ascertained by a decrease inAF488-labeled human recombinant proteins. Foci of labeled pro-
teins (green fluorescence) are visible in the cells. Nuclei were
stained with DAPI (blue).
Authors
Figure 5. iPSC-Based Modeling of ATTR In Vitro; ATTRL55P hs Deleteriously Affects iPSC-Derived Target Cells
(A) Mature ATTRL55P iPSC neuronal-lineage cells were exposed to hs from either control iPSCs or ATTRL55P iPSC hepatic-lineage cells. No
discernable differences in cell morphology and no visible protein aggregation were seen after 10 days. Images, 203 magnification.
(B) Cardiomyocytes derived from ATTRL55P iPSCs were exposed to hs for 6 days. There were no visible differences in the cultures containing
control hs and ATTRL55P hs (203 magnification).
(C and D) Gene expression analysis of day 12-dosed ATTRL55P neuronal cells (C) and day 10-dosed ATTRL55P cardiac cells (D) for a panel of
markers associated with stress response and protein folding. Error bars, SD. Asterisks (*, **) denote t test significance at the 5% and 1%
level, respectively. Sample size is n = 2 from independent experiments. ATTRL55P samples were normalized to controls for each experiment.
(E)ATTRneuronal cells cultured inmedia containinghs for 19dayswere analyzed for the uptakeof PI andHoechst 33342. Cultures dosedwith
ATTRL55P hs contained fewer live cells (forward versus side scatter gate; Hoechst-positive gate, annotated) compared to control hs cultures.
(F) ATTRL55P cardiac cells dosed for 10 days with media containing ATTRL55P hs exhibited a decrease in cell viability compared to control
cultures.
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iPSC-Based Modeling of Familial TTR Amyloidosisthe proportion of cells in the FSC versus SSC gate and an in-
crease in PI-positive cells (representative flow cytometry re-
sults in Figures 5E and 5F with compiled results in Figures
6B and 6D). Similar results had previously been observed
in preliminary experiments ascertaining the effect of re-Stem Cell Rcombinant human WT or L55P TTR on cell survival in
iPSC-derived neuronal (Figure S4A) and cardiac (Figure S4B)
cultures.
Thus, iPSC-derived hs containing amyloidogenic L55P
TTR had a deleterious effect on cell survival compared toeports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The Authors 457
Figure 6. The Deleterious Effects of ATTRL55P hs Can Be Abrogated by Small Molecule TTR-Stabilizing Agents
(A) ATTRL55P iPSC-derived neuronal-lineage cells were exposed to control and ATTRL55P hs in the presence or absence of diflunisal (20 mM)
and flufenamic acid (10 mM). Cells were harvested and examined for their H-PI positivity by flow cytometry. Increased apoptosis and cell
death seen in ATTRL55P hs cultures were rescued in cultures also containing the small molecule compounds.
(B) Neuronal live-cell proportions in cultures dosed with ATTRL55P hs for 12 days, ± compounds, compared to control hs-dosed cells. Error
bars, SD. Asterisks (*, **) denote t test significance at the 5% and 1% level, respectively. p Values are denoted in the graph. Sample sizes
(from independent experiments) are ATTRL55P n = 4, ATTRL55P + Diflu n = 3, and ATTRL55P + Fluf n = 3. n.s., not significant.
(C) ATTRL55P iPSC-derived cardiac cells were dosed for 6 days and analyzed for Hoechst-PI positivity in the same manner.
(D) Cardiac live-cell proportions in cultures dosed with ATTRL55P hs, ± compounds, compared to control hs-dosed cells. Error bars, SD.
Asterisks (*, **) denote t test significance at the 5% and 1% level, respectively. p Values are denoted in the graph. Sample sizes (from
independent experiments) are ATTRL55P n = 3, ATTRL55P + Diflu n = 3, and ATTRL55P + Fluf n = 3.
458 Stem Cell Reports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The Authors
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iPSC-Based Modeling of Familial TTR Amyloidosissupernatant from control-iPSC hepatocytes. Through the
examination of previously identified ATTR-associated
genes and genes identified through our iPSC-derived
hepatic-lineage microarray screen, we were able to deter-
mine that ATTRL55P hs exposure upregulated several
ATTR disease-associated genes in target cells, in a manner
that is similar to some reported observations in both in vivo
and in vitro systems.SmallMolecules CanAmeliorate theDamaging Effects
of ATTRL55P Exposure in an iPSC-Based, Multisystem
Model of ATTR
In vitro and clinical data demonstrate that small molecules
complexing with TTR at the thyroxine binding site can sta-
bilize the native tetramer, preventing amyloid fibril forma-
tion, and inhibiting disease progression (Coelho et al.,
2012; Miller et al., 2004; Peterson et al., 1998; Sekijima
et al., 2006; Tojo et al., 2006). To determine the effect of
TTR stabilizers in our iPSC-derived multiorgan model of
ATTR, we examined the effect of identified TTR-responsive
smallmolecules on ATTRL55P hs-induced apoptosis of iPSC-
derived cardiac and neuronal-lineage cells.
To ascertain whether diflunisal and flufenamic acid, two
thyroxine-mimetic small molecule TTR stabilizers, negate
the deleterious effects of ATTRL55P hs, these compounds
were added to ATTRL55P hs for dosing experiments with
neuronal and cardiac cells at final concentrations of 20
and 10 mM, respectively. As demonstrated in Figure 6, the
addition of the small molecules to ATTRL55P hs had a pro-
tective effect on both neuronal and cardiac cell survival
compared to cells exposed to ATTRL55P hs alone, as judged
by H-PI stainings of dosed cells. Although exposure of both
neuronal and cardiac cells to ATTRL55P hs led to a statisti-
cally significant decrease in cell survival compared to
control hs samples (Figures 6B and 6D), addition of
small molecule compounds resulted in increased cell sur-
vival (close to, but not significantly different compared
to ATTRL55P hs for ATTRL55P+diflunisal; significant for
ATTRL55P+flufenamic acid). These drugs were also capable
of preventing recombinant human L55P TTR protein
from forming microscopically visible protofilaments in
cultures of patient iPSC-derived neuronal cells and SY5Y
neuroblastoma cells, as assessed by thioflavin T binding
(Figures S4C–S4E). These experiments demonstrate that
an iPSC-based, multisystem, in vitro model can serve as a
valuable platform for the testing of novel therapeutics in
the genetic context of the patient.DISCUSSION
Human iPSC-based disease modeling provides an opportu-
nity to recapitulate a disease phenotype in the context of aStem Cell Rpatient’s exact genetic background. In the case of ATTR,
patients with the same geneticmutations have been shown
to exhibit variable patterns of disease progression (Plante´-
Bordeneuve and Said, 2011), highlighting the involvement
of genetic modifiers of disease.
ATTR is an unusual hereditary disease thatmanifests clin-
ically in adulthood with no reproductive pressure against
transmission of the disease. Until recently, diagnostics
were not available, and carriers could not be identified
before clinical disease onset, which typically occurs in the
fourth decade or later. In patients affected with the TTRL55P
mutation, the age of disease onset is earlier and the clinical
outcomemore severe (Jacobson et al., 1992), characteristics
that reflect greater instability of the mutant TTR tetramer
(Lashuel et al., 1998, 1999). Our work documents the
successful modeling of ATTR in vitro with the use of iPSC
technology, demonstrating that it is possible to model a
long-term, complex, multisystem disease in a relatively
short space of time, using lineage-specified cells derived
from patient-specific stem cells.
iPSCs have been utilized to model genetic diseases in a
single lineage in which the variant protein functions, for
example, Fanconi anemia (Raya et al., 2009), alpha 1 anti-
trypsin deficiency (Rashid et al., 2010), and amyotrophic
lateral sclerosis (Dimos et al., 2008). Our work demon-
strates that iPSC technology can be used to model a multi-
system disease in which the effects of variant protein
produced by one organ manifests disease in other target
tissues.
The mechanism by which variant TTR adversely affects
cells is still being elucidated. It is postulated that abundant
extracellular amyloid fibril deposits seen in patient biopsies
have a disruptive effect on tissue architecture and organ
function, but recent evidence suggests that TTRmonomers
and/or oligomeric prefibrillar protein structures are toxic to
cells (Reixach et al., 2004; Sousa et al., 2001a, 2002). We
have recapitulated a part of this process in a patient-specific
fashion in vitro. In our iPSC-based disease model, the lack
of visible protofilament/aggregate material in ATTRL55P hs
cultures suggests that the negative effect of ATTRL55P hs is
likely to be due to monomer or oligomer-induced cytotox-
icity, reported by others to be a mechanism of cellular
damage (Reixach et al., 2004; Sousa et al., 2002).
Although extended exposure to ATTRL55P hs increased
apoptosis in both neuronal and cardiac cells, we were inter-
ested in examining some of the molecular changes in the
exposed target-lineage cells. Based on the previously
discussed microarray data obtained through the compari-
son of hepatic cells derived from normal or ATTRL55P-spe-
cific iPSCs (Figure S2), we focused on expression of hsp70
family genes that are involved in protein folding and upre-
gulated in response to cellular stressors. These genes have
been studied in a range of protein-misfolding disorders,eports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 The Authors 459
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Intriguingly, an ATTR mouse model with impaired heat
shock response exhibits a comparatively accelerated amy-
loid deposition pattern, implicating the importance of
these genes for the regulation of the process of ATTR amy-
loidogenesis (Santos et al., 2010). We also examined the
expression of markers previously reported to be associated
with ATTR in othermodel systems and patient tissues, such
as M-CSF, p21, and antioxidant enzyme HO1 (Sousa et al.,
2001a, 2001b, 2005), and the receptor for advanced glyca-
tion end products (RAGE), a marker that has been postu-
lated as a mechanism through which variant TTR targets
certain tissues for amyloid deposition and cytotoxic effects
(Sousa et al., 2001b). Through the examination of these
markers in the exposed target-lineage cells, we were able
to determine a pattern of gene expression upregulation in
ATTRL55P hs-exposed cells that was accordant with previ-
ous observations. This iPSC-based, in vitro system may
therefore prove to be a valuable model system in which
to further dissect the molecular mechanisms through
which aberrant TTR affects ATTR disease target cells and
tissues. Moreover, it is interesting that in our system,
iPSC-derived ATTRL55P hepatic cells exhibit gene expres-
sion differences compared to control cells because the
livers of patients with ATTR are thought to be compara-
tively normal despite being the site of aberrant TTR
production. Recent findings from a murine SSA model
also suggest that the liver has a role to play in the degree
of amyloidogenesis in target tissues, through a novel
long-range chaperoning effect (Buxbaum et al., 2012).
The iPSC-based system may prove to be an ideal platform
in which to further investigate the role of the liver in
ATTR amyloidogenesis.
The ability of diflunisal and flufenamic acid, known TTR
tetramer stabilizers, to prevent iPSC-derived target cell
death in the presence of ATTRL55P hs validates this system
as a potential platform in which to test novel therapeutic
agents. Different approaches to therapeutically target the
cause and symptoms of ATTR have been tested in in vitro
and in vivo systems, with several progressing onto human
clinical trials. Examples include the reduction of serum
level TTR through the use of antisense technology (Acker-
mann et al., 2012), and the design of small molecule
compounds with the aim of either kinetically stabilizing
aberrant TTR heterotetramers (Alhamadsheh et al., 2011;
Connelly et al., 2010) (thus slowing the rate-limiting step
in the process of amyloidogenesis) or disruption of existing
amyloid fibrils and prefibrillar aggregates (Cardoso et al.,
2010; Ferreira et al., 2012). Patients with ATTR form amy-
loidogenic protein based on 1 of over 100 point mutations
in the TTR gene (Connors et al., 2003). The binding affinity
of smallmolecule inhibitors to different variant TTRs varies
significantly, predictingmutation-unique responses to spe-460 Stem Cell Reports j Vol. 1 j 451–463 j November 19, 2013 j ª2013 Thecific TTR stabilizers (Tojo et al., 2006), an indicator that a
one-size-fits-all approach to ATTR treatment may not be
feasible. Generation of differentiated, iPSC-derived, ATTR
disease-specific cells permits variant TTR-specific screening
of potential therapeutic molecules, overcoming issues of
incomplete mutation representation in clinical trials of
this rare orphan disease. These cells also provide a model
system in which to study genetic modifiers of TTR secre-
tion, and cytoprotective agents that inhibit toxic signaling
pathways in the target cells. Based on the fact that these dis-
ease-specific cells are pluripotent and can be stored and
expanded indefinitely, they will serve as a permanent re-
pository for researchers around the world as a valuable
tool for investigating potential new targets for drugsmodu-
lating protein misfolding and aggregation.EXPERIMENTAL PROCEDURES
STEMCCA Lentivirus Production, iPSC Generation
and Maintenance, and Teratoma Formation Assay
hSTEMCCA virus production and concentration (Sommer et al.,
2009, 2010) and iPSC generation, maintenance, and validation
were carried out as previously described by Somers et al. (2010).
For this study, fibroblasts from a 27-year-old female patient hetero-
zygous for the L55P TTRmutation were used to create three clonal
disease-specific lines. The three control iPSC lines used in this
study were obtained from the Boston University and Boston
Medical Center’s Center for Regenerative Medicine (CReM)
comprehensive iPSC bank (http://www.bumc.bu.edu/stemcells/
crem-ips-cell-bank/) and were matched with the disease-specific
lines for age, gender, and ethnicity.
Generation of Hepatic-Lineage Cells from iPSCs
Differentiation of iPSCs toward the hepatic lineage was carried out
as described by Hay et al. (2008) and Sullivan et al. (2010). For the
collection of media supernatants from hepatic-lineage cells, the
end-stage differentiated cells were washed with PBS and incubated
in serum-free media (L-15 [Leibovitz] medium, 10% KnockOut
Serum Replacement [KSR], and Penicillin-Streptomycin-Gluta-
mine, which were all from Invitrogen). The media were harvested
and replaced every 24 hr up to 3 days. See the Supplemental
Experimental Procedures for details regarding microarray analysis
of iPSC-derived hepatic-lineage cells. For the FACS analysis
of definitive endoderm markers, trypsin-dissociated cells were
stained with human CXCR4-biotin/strepavidin-FITC and cKit-PE
(eBiosciences) antibodies and analyzed on an LSRII (BD Biosci-
ences) using FACsDiva software.
Generation of Cardiomyocytes from iPSCs
Adherent cardiac cell cultures were specified based upon a previ-
ously described protocol by Kattman et al. (2011) and Yang et al.
(2008). For the EB differentiation protocol, confluent iPSC colonies
were treated with 1 mg/ml collagenase IV (Invitrogen), then
washed from the wells using a p1000 pipette tip. Cell clusters
were transferred to methylcellulose dishes in DMEM, 20% FBSAuthors
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7 days. The resultant EBs were transferred to gelatin-coated tissue
culture plates. Media were changed every 3 days.
For intracellular staining of cEB cells for sarcomeric anti-actinin,
trypsin-dissociated 4% paraformaldehyde (PFA):PBS-fixed cells
were washed and stained in PBS/5% FBS/0.5% saponin. The pri-
mary antibody was sarcomeric anti-actinin (Sigma-Aldrich), the
isotype control was mouse IgG1 k, and the secondary antibody
was FITC anti-mouse IgG (both from BD PharMingen). Analysis
was carried out on an LSRII flow cytometer.
Generation of Neuronal-Lineage Cells from ATTRL55P
iPSCs
Neuronal-lineage cells were generated as previously described by
Chambers et al. (2009) and Hu et al. (2009). For immunofluores-
cence visualization of TUJ1, MAP2, and ChAT, cells were
grown on 18 mm glass coverslips coated with 5 mg/ml fibro-
nectin and 10 mg/ml laminin (for TUJ1, MAP2 stainings) or
Matrigel (for ChAT stainings). Cells were fixed with 4% PFA in
PBS and permeabilized and blocked with 5% BSA in PBS with
0.1% Triton X-100. Primary and secondary antibody stainings
were carried out in PBS/0.005% Triton X-100. Primary antibodies
were mouse anti-human Tuj1, mouse anti-human MAP2 (Sigma-
Aldrich), and rabbit anti-human ChAT (Millipore). Secondary
antibodies were donkey anti-mouse 594 nm and donkey anti-rab-
bit 488 nm (Jackson ImmunoResearch). Cell nuclei were stained
with DAPI (Molecular Probes) after antibody incubations and
final washes.
PAS Assays
PAS assays were carried out on adherent cell cultures in 6-well
plates, based on manufacturer recommendations (Invitrogen).
Cells were visualized and photographed using a Nikon Eclipse
TS100 microscope and SPOT software (SPOT Imaging Solutions).
Immunoblot Analysis
A total of 25 ng of purified human serum TTR (Sigma-Aldrich),
hepatic-iPSC supernatant, and KSR-based media control samples
were analyzed by SDS/PAGE using a 12% homogeneous gel under
reducing conditions. Rabbit anti-human TTR (DAKO) and HRP-
conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology)
were used for TTR detection. The immunoblot was developed
using the ECL Plus Western Blotting Detection Reagent (GE
Healthcare).
Mass Spectrometry
TTR protein was purified from culture supernatants by immuno-
precipitation and characterized by electrospray ionization (ESI)
mass spectrophotometry (Lim et al., 2002).
Thioflavin T Assay
Cell andmedia cytospins were fixed in 4% PFA for 10 min, washed
with distilled water, and stained with 1% thioflavin T solution for
5 min. The cells were then differentiated in 70% ethanol and
rinsed twice with distilled water before being mounted for micro-
scopy under polarized light.Stem Cell RRNA Extraction, and Semiquantitative and
Quantitative PCR
The RNeasyMicro Kit (QIAGEN), DNA-free Kit (Ambion), andHigh
Capacity cDNA Reverse Transcription Kit (Applied Biosciences)
wereused for the extractionandpurificationof RNAandcDNAsyn-
thesis, all according to manufacturer instructions. Quantitative
PCR was conducted using SYBR Green Real-Time PCR Master Mix
(Applied Biosystems) and StepOne Real-Time PCR machines
(AppliedBiosystems). SeeTableS1 for a listofprimers.Whereappro-
priate, Student’s t test statistical analyses were carried out to deter-
mine if there were significant differences between sample groups.
Cell Viability Assays
Fordosingexperiments involvinghs,filteredsupernatants collected
from iPSC-hepatic cultures were diluted 1:1 with neuronal/cardiac
growth media as appropriate before addition to cell cultures. For
experiments involving small molecules, diflunisal and flufenamic
acid were added to supernatants and incubated at 4C overnight
before addition to cell cultures (final concentrations, 20 and
10 mM, respectively). Dosed cell cultures were trypsin dissociated
and washed with PBS-5% FBS before incubation with 8.8 ng/ml
Hoechst 33342 (Sigma-Aldrich) at 37C for 15 min. After washes,
the cells were incubated with PI (Invitrogen) and immediately
analyzed by flow cytometry (LSRII). For statistical analyses, a value
for cell survival for each samplewas calculated from the proportion
of cells in the FSc versus SSc gate and the proportion of Hoechst-
positive, PI-negative cells within this population. Samples were
normalized to the control sample for each experiment. Student’s
t tests were conducted to compare ATTRL55P to control, ATTRL55P
plus diflunisal, and ATTRL55P plus flufenamic acid groups. See the
Supplemental Experimental Procedures for details of experiments
involving recombinant TTR protein.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, one table, and one movie and can be
found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2013.10.003.
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